Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70

Trial Profile

A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Cusatuzumab (Primary)
  • Indications Cutaneous T-cell lymphoma; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 04 Dec 2018 Results (Data cut off, 26 June 2018, n=27), presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 31 Aug 2018 Biomarkers information updated
    • 08 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top